Clinical Trial Update: A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating efficacy, safety, and pharmacokinetics of XP21279 with Sinemet in Parkinson's disease completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• SINEMET (carbidopa and levodopa)
• XP21279

Snippet

Sponsor: XenoPort, Inc. | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED